Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
Halozyme Therapeutics (NASDAQ: HALO) has announced its participation in the upcoming TD Cowen 45th Annual Healthcare Conference. Dr. Helen Torley, president and chief executive officer, will deliver a presentation on Wednesday, March 5 at 8:50am PT / 11:50am ET.
The company will provide a live audio webcast of the presentation through their Investor Relations website section. The webcast recording will remain accessible for 90 days following the conference, allowing investors and interested parties to review the presentation at their convenience.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato la sua partecipazione al prossimo 45° Congresso Annuale sulla Salute di TD Cowen. La Dr.ssa Helen Torley, presidente e amministratore delegato, terrà una presentazione mercoledì 5 marzo alle 8:50 PT / 11:50 ET.
L'azienda fornirà un webcast audio in diretta della presentazione attraverso la sezione del sito dedicata alle Relazioni con gli Investitori. La registrazione del webcast rimarrà accessibile per 90 giorni dopo la conferenza, consentendo agli investitori e alle parti interessate di rivedere la presentazione con comodità.
Halozyme Therapeutics (NASDAQ: HALO) ha anunciado su participación en la próxima 45ª Conferencia Anual de Salud de TD Cowen. La Dra. Helen Torley, presidenta y directora ejecutiva, realizará una presentación el miércoles 5 de marzo a las 8:50 a.m. PT / 11:50 a.m. ET.
La compañía ofrecerá un webcast de audio en vivo de la presentación a través de la sección de Relaciones con Inversores de su sitio web. La grabación del webcast permanecerá accesible durante 90 días después de la conferencia, permitiendo a los inversores y partes interesadas revisar la presentación a su conveniencia.
Halozyme Therapeutics (NASDAQ: HALO)는 다가오는 TD Cowen 제45회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 헬렌 토를리 박사, 사장 겸 CEO가 3월 5일 수요일 오전 8:50 PT / 오후 11:50 ET에 발표를 진행할 예정입니다.
회사는 투자자 관계 웹사이트 섹션을 통해 발표의 실시간 오디오 웹캐스트를 제공할 것입니다. 웹캐스트 녹화는 컨퍼런스 이후 90일 동안 접근 가능하여 투자자와 이해관계자들이 편리하게 발표를 검토할 수 있습니다.
Halozyme Therapeutics (NASDAQ: HALO) a annoncé sa participation à la prochaine 45e Conférence Annuelle de Santé de TD Cowen. Dr. Helen Torley, présidente et directrice générale, présentera une intervention le mercredi 5 mars à 8h50 PT / 11h50 ET.
L'entreprise proposera un webinaire audio en direct de la présentation via la section Relations Investisseurs de son site web. L'enregistrement du webinaire restera accessible pendant 90 jours après la conférence, permettant aux investisseurs et aux parties intéressées de revoir la présentation à leur convenance.
Halozyme Therapeutics (NASDAQ: HALO) hat seine Teilnahme an der bevorstehenden 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Dr. Helen Torley, Präsidentin und CEO, wird am Mittwoch, den 5. März um 8:50 Uhr PT / 11:50 Uhr ET eine Präsentation halten.
Das Unternehmen wird über den Bereich Investor Relations auf seiner Website einen Live-Audio-Webcast der Präsentation anbieten. Die Aufzeichnung des Webcasts bleibt 90 Tage nach der Konferenz verfügbar, sodass Investoren und Interessierte die Präsentation nach Belieben überprüfen können.
- None.
- None.
The presentation is scheduled for Wednesday, March 5 at 8:50am PT / 11:50am ET.
A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-td-cowen-45th-annual-healthcare-conference-302385786.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When is Halozyme (HALO) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Halozyme's TD Cowen conference presentation?
How long will Halozyme's TD Cowen conference presentation replay be available?
Who is representing Halozyme (HALO) at the TD Cowen Healthcare Conference?
